Targacept to Discontinue Overactive Bladder Program

July 28, 2014 9:37 PM

11 0

Targacept Inc. said it would abandon further development of TC-5214 as a treatment for overactive bladder after seeing disappointing results in a midstage study.

“The results were not compelling enough to justify the compound’s continued development in overactive bladder,” said Dr. Stephen A. Hill, the company’s president and chief executive officer.

Also read: Novartis Tests New Alzheimer’s Drug on People Who Don’t Have the Disease

Read more

To category page